CEO of major Mass. health insurer discusses choice to restrict GLP-1 weight-loss drugs
Patrick Gilligan reached his one-year milestone as CEO of Point32Health, the organization that oversees Harvard Pilgrim Health Care and Tufts Health Plan. His first year in the role was marked by a shift in how the insurer manages rising costs and pharmaceutical expenses. The company decided to restrict access to GLP-1 weight-loss drugs as a response to the financial pressure caused by these treatments.
This decision arrived during a period of broader economic challenges for the insurance industry, including the lingering effects of the pandemic and significant cost increases for healthcare services. Alongside policy changes regarding medication coverage, the company went through a period of staff layoffs. Despite these operational changes, financial results indicate a recovery in performance for the insurer.
Point32Health reported an operating income of $86 million for the first quarter of 2026. This is a contrast to the $39 million loss the company recorded during the same period in 2025. Gilligan continues to navigate the balance between maintaining coverage standards and managing the financial stability of the insurer in a high-cost environment.